


Your Generics & Biosimilars Industry

Driving Prescription Drug Access and Affordability in New Mexico

August 10, 2022 | Brett Michelin




Generics Are Manufactured Across the U.S.





Generics As a Share of U.S. Health Care Spending

GENERIC DRUGS ACCOUNT FOR ONLY 3% OF TOTAL U.S. HEALTH CARE SPENDING




Source: Peterson-KFF Health System Tracker, "What drives health spending in the US compared to other countries," September 25, 2020. https://www.healthsystemtracker.org/brief/what-drives-health-spending-in-the-us-compared-to-other-countries Note: Generic and brand drug share of prescription drug spending was calculated using an analysis of the 2018 Medical Expenditure Panel Survey (MEPS). Total drug spending was segmented into generics and brands. Those percentages were then applied to the Peterson-KFF Health System Tracker analysis of spending, by type of expenditure, in the US healthcare system.



Generics Account For Only 16% Of Total Medicine Purchases but 92% Of All Prescriptions Dispensed and 65% Of Patient Out of Pocket Costs

GENERICS AND BRANDED GENERICS ACCOUNT FOR 16% OF INVOICE-LEVEL SPENDING BUT REPRESENT 65% OF PATIENT OUT-OF-POCKET COSTS



Share of spending, prescriptions and patient out-of-pocket costs by product type, 2017–2021



Source: IQVIA National Sales Perspectives; IQVIA National Prescription Audit; IQVIA LAAD Sample Claims Data, Dec 2021.



Generic Drug Supply Chain









Brand Drug Supply Chain

SPREAD OF \$100 ACROSS THE BRAND DRUG SUPPLY CHAIN




Savings From Generics and Biosimilars Totaled \$338 Billion in 2020

GENERIC AND BIOSIMILAR SAVINGS INCREASED BY \$23.5 BILLION FROM 2019 TO 2020






Savings From Generic Medicines by State, 2020



GENERIC DRUGS SAVE NEW MEXICANS MILLIONS

In 2020, New Mexico saved \$1.7 billion with generic and biosimilar medicines.

Patients win when FDA-approved generics and biosimilars deliver savings on their medicines. Market-based competition drives prices down, but meaningful action is needed to lower brand prescription drug costs while ensuring sustainable competition in the pharmaceutical sector.





The Top 10 Medicines of 2020 Saved \$99.1 Billion in 2020

THE TOP 10 PRODUCTS REPRESENT 29% OF THE OVERALL SAVINGS IN THE PAST 10 YEARS

TOP 10 MEDICINES WITH GREATEST SAVINGS IN 2020


Products	Generic Entry Year	Brand Pre-Expiry Price (per unit)	Price of Generic Equivalent 2020 (per unit)	2020 Savings (\$Bn)	Percent Savings	2020 Dispensed Rxs (Mn)
Lipitor	2011	\$3.29	\$0.08	\$19.2	98%	5982
Zofran	2006	\$21.67	\$0.16	\$13.9	99%	745
Prilosec	2002	\$3.31	\$0.06	\$12.0	98%	4116
Crestor	2016	\$5.78	\$0.08	\$10.7	99%	1899
Abilify	2015	\$21.68	\$0.40	\$8.9	99%	423
Neurontin	2004	\$1.02	\$0.07	\$7.5	93%	7864
Norvasc	2007	\$1.54	\$0.02	\$7.4	99%	4799
Singulair	2012	\$3.74	\$0.09	\$6.6	98%	1821
Cymbalta	2012	\$4.61	\$0.21	\$6.5	96%	1462
Protonix	2005	\$3.63	\$0.03	\$6.2	98%	2290

Source: IQVIA, National Sales Perspectives, Dec 2020




Savings From Generic Medicines by Primary Patient Condition

GENERICS SAVED AMERICANS WITH COMMON CONDITIONS BILLIONS



Generic Copays Are About 8.5 Times More Affordable Than Brands

93% OF GENERIC COPAYS ARE BELOW \$20, COMPARED TO ONLY 51% OF BRANDS




Note: Includes commercial, Medicare Part D and Medicaid channels; Limited to standard market baskets. Source: IQVIA LAAD dataset; US Market Access Strategy Consulting analysis.



Abandoned Prescriptions: Health Consequences

PATIENTS ARE MORE LIKELY TO ABANDON COSTLY BRAND PRESCRIPTIONS



Biosimilars Market Overview



37 approved

Projected savings through 2025 \$133 Billion

22 marketed

Biosimilars have been used in more than **121 million days** of patient therapy and have resulted in almost **10 million incremental days** of therapy.


> Approval / Marketing data as of August 2022. Source: U.S. FDA. Patient day data developed by Biosimilars Council with IQVIA



Biosimilars Are Less Expensive Than Their Reference Brand Biologic

BIOSIMILAR COMPETITION HAS BEEN STABLE AND PROVIDES CONSISTENT SAVINGS






Source: IQVIA Institute (October 2020) "Biosimilars in the United States 2020-2024; Competition Savings and Sustainability."



Biosimilar Savings Totaled \$7.9 Billion in 2020

SAVINGS FROM BIOSIMILAR USE MORE THAN TRIPLED FROM 2019




Source: IQVIA, National Sales Perspectives, Dec 2020



Biosimilars Projected to Save \$133 Billion by 2025

SAVINGS WILL DEPEND ON APPROPRIATE POLICIES TO SUPPORT ADOPTION



AAM's Prescription for State Savings





Prescription for State Savings

Preserve Patient Access to Generics and Biosimilars

• State proposals often negatively impact generic and biosimilar manufacturers through one-size-fits-all policies or with onerous requirements that threaten continued patient savings.

Combat Misinformation, Promote the Use of Biosimilars

• States could make available and distribute FDA's biosimilar materials, conduct studies on the savings to patients and payers derived from these new treatments, and help raise awareness about the use of biosimilar medicines.

Ensure Coverage of Cost-Effective Biosimilar Medicines


• States could take steps to encourage the coverage and use of biosimilar medicines by addressing payer and provider barriers.

Lower Patient OOP Costs with Generics on Generic Tiers

• Ensuring coverage of newly available generic medicines and proper formulary tier coverage would reduce patient cost-sharing.

Advance Incentives for U.S.-Based Manufacturing

• State-based tax incentives and economic development grants could be provided to support domestic manufacturing and help ensure patients have access to a secure and consistent supply of critical medicines.



- Ensure Coverage of Cost-Effective Biosimilar Medicines
- ✓ Lower Patient Out-of-Pocket Costs with Generics on Generic Tiers
- Advance New Tax and Other Financial Incentives to Enhance U.S.-Based Manufacturing



#R4STATESAVINGS

Prioritizing Biosimilars through Formulary Design



Biosimilar vs Interchangeable is not relevant for formulary regulations. The distinction is only meaningful at the pharmacy counter and is not an indication of superior quality.

Biosimilars

FDA-Approval

 Highly similar to the reference product and does not have clinically meaningful differences

Administration

 Prescribed <u>and administered</u> by a physician or other health care provider

Interchangeable Biosimilars

FDA-Approval

- Biosimilar
- Per FDA's requirements, may have undergone additional studies about the effects of switching between biosimilar and reference


Administration

- Typically dispensed by a pharmacist
- Subject to state law, a pharmacist may substitute an interchangeable biosimilar instead of the reference without the prescribing physician's approval



Price Transparency & Affordability Board Proposals Mistakenly Target Generics

EXAMPLES ARE OFTEN MISLEADING




AAM Position Exempt Medicines with <= \$100 WAC for a 30day Supply



Patent Settlements Promote a Competitive Market

FTC Reports Dramatic Decline in Reverse-Payment Agreements Following Actavis Decision



Settlements With Restriction on Generic Entry and Compensation (Excluding Litigation Fees) as Reported by FTC

Source Notes: The bar chart reflects data included in FTC's annual staff report on patent settlement agreements. The most recent report released in December 2020 is for FY2017 and includes the number of patent settlement agreements with restrictions on entry and compensation above \$7.5 million. The data displayed is provided for illustrative purposes only and does not reflect how AAM would characterize the agreements in question.